NEW YORK, July 29 -- The National Multiple Sclerosis Society issued the following news:

* * *

- Top-line results were announced from a Phase 3 study comparing oral ponesimod (The Janssen Pharmaceutical Companies of Johnson & Johnson) to Aubagio(R) (teriflunomide, Sanofi Genzyme).

- According to a company press release, the study met primary and most secondary endpoints, significantly reducing the annual relapse rate in adults with relapsing MS.

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Submit Form Click here for more information about our products